cardura xl 8 mg tablete s podaljšanim sproščanjem
pfizer luxembourg sarl - doksazosin - tableta s podaljšanim sproščanjem - doksazosin 8 mg / 1 tableta - doksazosin
cardosin retard 4 mg tablete s podaljšanim sproščanjem
actavis group ptc ehf. - doksazosin - tableta s podaljšanim sproščanjem - doksazosin 4 mg / 1 tableta - doksazosin
lekoklar xl 500 mg tablete s podaljšanim sproščanjem
lek d.d. - klaritromicin - tableta s prirejenim sproščanjem - klaritromicin 500 mg / 1 tableta - klaritromicin
lekoklar xl 500 mg tablete s podaljšanim sproščanjem
lek d.d. - klaritromicin - tableta s prirejenim sproščanjem - klaritromicin 500 mg / 1 tableta - klaritromicin
lekoklar xl 500 mg tablete s podaljšanim sproščanjem
lek d.d. - klaritromicin - tableta s prirejenim sproščanjem - klaritromicin 500 mg / 1 tableta - klaritromicin
lekoklar 250 mg filmsko obložene tablete
lek d.d. - klaritromicin - filmsko obložena tableta - klaritromicin 250 mg / 1 tableta - klaritromicin
lekoklar xl 500 mg tablete s podaljšanim sproščanjem
lek d.d. - klaritromicin - tableta s prirejenim sproščanjem - klaritromicin 500 mg / 1 tableta - klaritromicin
lekoklar 500 mg filmsko obložene tablete
lek d.d. - klaritromicin - filmsko obložena tableta - klaritromicin 500 mg / 1 tableta - klaritromicin
adempas
bayer ag - riociguat - hipertenzija, pljučnica - antihipertenzivi za pljučno arterijsko hipertenzijo - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. učinkovitosti je bil prikazan v pah prebivalstva, vključno z aetiologies z idiopatsko ali dedne pah ali pah, povezanih z vezivnega tkiva bolezni. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastična sredstva - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.